Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Copper gel shows promise for faster wound healing in new trial

NCT ID NCT07437586

Symptom relief Sponsor: Hudson Biotech Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a topical gel containing GHK-Cu, a copper-peptide complex, to see if it can safely speed up healing of small, standardized skin wounds in healthy adults. Sixty participants will each get two small wounds on their arm; one wound gets the active gel, the other a placebo gel. Healing is tracked with photos and exams over three weeks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 to 55 years at screening. * Healthy adult as determined by medical history and limited physical examination. * Body mass index (BMI) 18.0 to 30.0 kg/m². * Willing and able to comply with study visits and daily product application for 14 days. * Willing to avoid applying non-study topical products (including medicated creams, retinoids, acids) to the wound area during the study period. * For participants of childbearing potential: negative pregnancy test at screening and agreement to use effective contraception through Day 21. Exclusion Criteria: * Known allergy or sensitivity to copper, peptides, gel excipients, adhesives, or dressings used in the study. * History of abnormal wound healing, hypertrophic scarring, or keloid formation. * Clinically significant dermatologic disease near the intended wound site (e.g., eczema, psoriasis, active infection). * Diabetes mellitus, peripheral vascular disease, immunodeficiency, or other condition that may impair wound healing (investigator judgment). * Use of systemic corticosteroids, immunosuppressants, or cytotoxic medications within 30 days prior to Day 0. * Current smoker or nicotine use (including vaping) within the past 3 months. * Pregnant or breastfeeding. * Participation in another interventional clinical study within 30 days prior to screening. * Any condition that, in the investigator's opinion, would make participation unsafe or could interfere with study assessments.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute standardized cutaneous wounds (punch-biopsy wounds) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute standardized cutaneous wounds (punch-biopsy wounds)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Peking University Shenzhen Hospital

    RECRUITING

    Shenzhen, Guangdong, 518036, China